In summary, we present compelling evidence that in a select subgroup of breast cancers, loss of Gal3 is associated with a mesenchymal BCSC subtype and enhanced tumorigenicity, predicts poor response to chemotherapy, and therefore correlates with poor prognosis. This evidence concerns the gene LGALS3 and breast cancer.